Drugs / APC148
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06360640 | Sep 2024 → Mar 2025 | — | AdjuTec Pharma AS | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-06-23 | AdjuTec Pharma AS | Results Phase I Clinical Study Results for APC148 Published adjutecpharma.com ↗
The results demonstrated that APC148 was well tolerated and supported its continued clinical development as a potential solution to combat antibiotic-resistant bacterial infections caused by MBL-producing pathogens. |
| 2024-05-08 | AdjuTec Pharma AS | Regulatory AdjuTec Pharma Obtained Approval for their First Clinical Trial (Phase 1) adjutecpharma.com ↗
The Company has received approval to start its first APC148 phase 1 clinical trial by the Swedish medical products agency. |
| 2024-02-14 | AdjuTec Pharma AS | Regulatory AdjuTec Pharma Submits First Clinical Trial Application (CTA) adjutecpharma.com ↗
Today the Company submitted the first CTA to the Swedish Medicinal Product Agency (MPA) to start a clinical phase 1 study with its lead compound APC148. |
| 2023-02-02 | AdjuTec Pharma AS | Results AdjuTec Pharma Presentations Accepted at European Antimicrobial Conference (ECCMID) adjutecpharma.com ↗
In one presentation, the company lead compound (APC148) in combination with a broad-spectrum antibiotic, shows low frequencies of resistance in the tested bacterial strains. |
| 2022-06-13 | AdjuTec Pharma AS | Regulatory AdjuTec Pharma Receives QIDP Designation from the U.S. FDA for the Development of APC148 in combination with meropenem adjutecpharma.com ↗
AdjuTec Pharma, a privately held company developing novel antibiotic resistance breakers, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Adjutec a Qualified Infectious Disease Product (QIDP) designation to its lead product APC148 and meropenem. |
| 2021-09-10 | AdjuTec Pharma AS | Regulatory AdjuTec Pharma Strengthens the Patent Portfolio adjutecpharma.com ↗ |
All press releases naming this drug 13 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APC148 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06360640 ↗ |
| Action | Inhibit | “APC148 is a novel metallo-β-lactamase inhibitor with broad activity against Ambler class B enzymes, including NDM, VIM, and IMP.” PMID 42307233 ↗ Jun 2026 |
| Route | Intravenous | “The purpose of this first-in-human trial is to investigate the safety, tolerability, and pharmacokinetics of APC148 after intravenous (IV) infusion of single ascending doses in...” NCT06360640 ↗ |